Hemophilia A clinical trials
The registry lists 844 studies for Hemophilia A across more than 10 countries. 136 are recruiting or about to start. 779 of them are mainly about Hemophilia A (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.
ClinicalTrials.gov finds 945 studies for Hemophilia A. How that becomes 843 here
This page counts the studies the registry files under Hemophilia A, and those it files under no condition that list Hemophilia Athemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count
- 945Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
- −75List Hemophilia A as a condition, but the registry did not file them under itMost often written as “Hemophilia B” (45), “Haemophilia B” (11), and “Acquired Hemophilia A” (10). The registry filed them under other conditions only, most often Hemophilia B (57) and Factor 8 deficiency, acquired (11).
- −32Match it another way7 name it in the title, 1 in a keyword, and 24 by a synonym or other text the search reads.
- 838Counted here and found by its search49 of them list Hemophilia A in their own words; the registry filed them under no condition.
- +5
Counted here, but its search does not find them
- Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)NCT01808911
- Comparison of Two Types of Ankle Braces in the Management of Ankle Pain in HemophiliaNCT00972296
- Prospective Clinical and Biological Follow-up of Acquired Haemophilia : SACHA StudyNCT00213473
- Compassionate Use of Concizumab if You Have HaemophiliaNCT04921956
- Quality of Life in Hemophilia by Clinical Scoring System (FISH)ScoreNCT04102046
- 843The count on this page
Get an email when these change. Save the Hemophilia A studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Novo Nordisk A/S (92) · Bayer (57) · Baxalta now part of Shire (40) · Pfizer (35) · Investigación en Hemofilia y Fisioterapia (21) · Hoffmann-La Roche (17) · Swedish Orphan Biovitrum (15) · Octapharma (15)
What is being tested here
Drugs under test in Hemophilia A studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Nov 2026To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A · Phase 3 · Gritgen Therapeutics Co., Ltd.
- Dec 2026Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A · Phase 3 · Jiangsu Gensciences lnc.
- Jan 2027Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A · Phase 3 · Bioverativ, a Sanofi company
- Feb 2027Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment · Phase 3 · Hangzhou Gensciences Biopharmaceutical Co., Ltd.
- Mar 2027Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa · Phase 3 · Swedish Orphan Biovitrum
- Mar 2027Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment. · Phase 3 · Hangzhou Gensciences Biopharmaceutical Co., Ltd.
- Mar 2027A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia · Phase 3 · Sanofi
- May 2027Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs · Phase 3 · Shanghai Xinzhi BioMed Co., Ltd.
- Sep 2027A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A · Phase 3 · Hoffmann-La Roche
- Sep 2027A Phase III Clinical Trial Evaluating SR604 Injection for Prophylactic Treatment in Patients With Hemophilia · Phase 3 · Shanghai RAAS Blood Products Co., Ltd.
Who these studies take
Of the 86 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 30 (35%) stop at 75 or younger. 54 (63%) take children under 18. 2 (2%) are for women only and 42 (49%) for men only; 10 (12%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 23 (27%) | 36 (42%) |
| 18 | 42 (49%) | 77 (90%) |
| 30 | 39 (45%) | 75 (87%) |
| 40 | 39 (45%) | 74 (86%) |
| 50 | 39 (45%) | 72 (84%) |
| 65 | 38 (44%) | 67 (78%) |
| 75 | 34 (40%) | 55 (64%) |
| 85 | 34 (40%) | 52 (60%) |
Across all 844 studies, recruiting or not: 47% stop at 75 or younger and 41% at 65; 66% take children; 2% are for women only and 60% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Hemophilia A studies take
Of 91 phase 3 interventional studies under Hemophilia A, half reached primary completion within 33 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 13 mo7–26 · 46 studies | 10 mo5–18 · 37 studies | — |
| Phase 1/2 | 76 mo21–94 · 20 studies | — | — |
| Phase 2 | 13 mo8–20 · 18 studies | — | — |
| Phase 3 | 33 mo20–56 · 91 studies | 32 mo18–56 · 89 studies | — |
| Phase 4 | 31 mo13–112 · 39 studies | — | — |
| Interventional, no phase | 11 mo5–38 · 75 studies | — | 11 mo5–38 · 72 studies |
| Observational | 45 mo25–79 · 131 studies | 58 mo34–79 · 53 studies | 36 mo15–96 · 78 studies |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 14, 2026.
Started recruiting2
Stopped1
- SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisWithdrawnNov 6, 2026NCT04563520
Newly registered4
- A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B Without InhibitorsNov 9, 2026NCT07923981
- Safety of Intraosseous Anaesthesia in Children With HaemophiliaNov 4, 2026NCT07916467
- A Study to Describe Patient REal-world FitusiRan ExpeRienceOct 26, 2026NCT07895381
- A Phase III Clinical Trial Evaluating SR604 Injection for Prophylactic Treatment in Patients With HemophiliaOct 15, 2026NCT07876674
Studies
Recruiting first, then most recently updated. Showing 50 of 844. Browse all 844 → or search them.
- A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia ARecruitingNCT07226206Phase 1/21 country
- A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B Without InhibitorsRecruitingNCT07923981Phase 31 country
- Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial HypertrophyRecruitingNCT06941870Phase 45 countries
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia ARecruitingNCT05987449Phase 1/26 countries
- Safety of Intraosseous Anaesthesia in Children With HaemophiliaNot yet recruitingNCT07916467Not applicable1 country
- A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia ARecruitingNCT07416604Phase 322 countries
- Lentiviral FVIII Gene TherapyNot yet recruitingNCT03217032Phase 11 country
- A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia ARecruitingNCT07830732Phase 318 countries
- A First-in Human Study of ARD001 in Healthy Volunteers and People With Hemophilia ARecruitingNCT07787091Phase 1/21 country
- A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or BRecruitingNCT07285460Phase 312 countries
- A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia ARecruitingNCT07416526Phase 318 countries
- A Study to Describe Patient REal-world FitusiRan ExpeRienceNot yet recruitingNCT078953811 country
- Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without InhibitorsRecruitingNCT05145127Phase 324 countries
- An Observational Study to Learn More About How Well Damoctocog Alfa Pegol Works in Previously Treated Children With Hemophilia ARecruitingNCT0708845811 countries
- Liver Biopsy Following Gene Therapy For HemophiliaNot yet recruitingNCT059329141 country
- Development of Non-Invasive Prenatal Diagnosis for Single Gene DisordersRecruitingNCT061474141 country
- Post Approval Phase 4 Study to Learn More About How Safe Octocog Alfa is, and How Well it Works in Patients With Severe Hemophilia A in IndiaNot yet recruitingNCT07446010
- Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and ChildrenNot yet recruitingNCT07838194Phase 3
- A Phase III Clinical Trial Evaluating SR604 Injection for Prophylactic Treatment in Patients With HemophiliaNot yet recruitingNCT07876674Phase 3
- A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.RecruitingNCT06703606Phase 13 countries
- 3D Ultrasound in Hemophilic AnklesEnrolling by invitationNCT07452575Not applicable1 country
- A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia BRecruitingNCT05611801Phase 323 countries
- Identification of New Biomarkers in Haemophilic Arthropathy Through Transcriptome AnalysisRecruitingNCT07867821Not applicable1 country
- Tight Control of Treatment Adherence and Efficacy by Telemedicine for an Improved Personalized Management of Patients With HemophiliaRecruitingNCT07867834Not applicable1 country
- Determinants and Consequences of the Transition to Adulthood for Adolescents With Severe Haemophilia: TRANSHEMO 2, an Ancillary Study to the TRANSHEMO ProjectRecruitingNCT074188271 country
- Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa PegolEnrolling by invitationNCT046821451 country
- Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B RespectivelyRecruitingNCT05568719Phase 313 countries
- Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in GermanyEnrolling by invitationNCT076531391 country
- Multicomponent Pain Self-Management in Adults With Haemophilic ArthropathyNot yet recruitingNCT07860632Not applicable1 country
- A Study to Learn About the Study Medicine (Called Marstacimab) in People With Hemophilia A or BNot yet recruitingNCT07859527
- A Prospective Assessment of Bone Health in Patients With Severe Hemophilia A on Factor VIII vs Factor Mimetic Prophylaxis (Efa Emi Bone Health Study)RecruitingNCT075822761 country
- A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With HemophiliaRecruitingNCT07681089Phase 21 country
- Validity and Reliability of the Figure-of-Eight Walking and Weight-Bearing Lunge Tests in HemophiliaRecruitingNCT078519221 country
- TG-INSIGHT With Joint POCUS, Hemostatic Potential in Patients With Severe Hemophilia A on Novel Replacement and Substitution FVIII TherapiesRecruitingNCT076922171 country
- Efanesoctocog Prophylaxis Or The Optimization Of Treatment: Real-World Experience Of Taylorizing Clotting Therapy In Hemophilia ANot yet recruitingNCT078306931 country
- A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With EmicizumabRecruitingNCT06145373Phase 42 countries
- Treatment of Hemophilia A Patients With FVIII InhibitorsRecruitingNCT040230192 countries
- A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia ARecruitingNCT07220564Phase 112 countries
- Prevalence of Inhibitor Development in Hemophilia A Patients Receiving Coageight: A Multicenter Cross-sectional Observational StudyNot yet recruitingNCT077918361 country
- A Study of Elranatamab for Inhibitor Eradication in Patients With Hemophilia ANot yet recruitingNCT07788469Not applicable1 country
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)RecruitingNCT042784042 countries
- ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic DisordersRecruitingNCT043986281 country
- Ultrasound Assessment of Joint Health in Patients With Mild Hemophilia (Factor Levels 5-40%)Not yet recruitingNCT07719647Not applicable1 country
- Understanding Treatment Outcomes and Immunologic Mechanisms in Altuviiio Immune Tolerance InductionNot yet recruitingNCT07158606Phase 41 country
- Study of Surgical Practices in Hemophilia A Patients Treated With Efanesoctocog Alfa (Altuvoct®)RecruitingNCT077235601 country
- Study of a Smart Sharps Disposal Device in Patients With HemophiliaNot yet recruitingNCT07421154Not applicable1 country
- Multimodal Telerehabilitation Versus Face-to-Face Care for Adults With Hemophilia and Chronic PainRecruitingNCT07682519Not applicable1 country
- Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab ProphylaxisRecruitingNCT050224591 country
- A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)RecruitingNCT06349473Phase 12 countries
- A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Participants With Hemophilia ARecruitingNCT062226971 country